Extended Analysis for Leukemia/Lymphoma Treatment

CompletedOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 30, 2020

Study Completion Date

January 30, 2020

Conditions
Relapsed Hematologic Malignancy
Interventions
DRUG

ngFDS selected treatment

Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).

Trial Locations (1)

1090

Medical University Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT03096821 - Extended Analysis for Leukemia/Lymphoma Treatment | Biotech Hunter | Biotech Hunter